Introduction Men who have sex with men (MSM) are one of the most at-risk group for contracting HIV in the USA. However, the HIV epidemic impacts some groups of MSM disproportionately. Latino MSM comprise 25.1% of new HIV infections among MSM between the ages of 13 and 29 years. The daily medication tenofovir/emtricitabine was approved by the Food and Drug Administration for pre-exposure prophylaxis (PrEP) in 2012 and has demonstrated strong efficacy in reducing HIV acquisition.
Methods and analysis Through extensive formative research, this study uses a pilot randomised controlled trial design and will examine the feasibility and acceptability of a patient navigation intervention designed to address multiple barriers to improve engagement in the PrEP continuum among 60 Latino MSM between the ages of 18 and 29 years. The patient navigation intervention will be compared with usual care plus written information to evaluate the feasibility and acceptability of the intervention and study methods and the intervention’s potential in improving PrEP continuum behaviours. The results will be reviewed for preparation for a future full-scale efficacy trial.
Ethics and dissemination This study was approved by the institutional review board at San Diego State University and is registered at ClinicalTrials.gov. The intervention development process, plan and the results of this study will be shared through peer-reviewed journal publications, conference presentations and healthcare system and community presentations.
Registration details Registered under the National Institutes of Health’s ClinicalTrials.gov (NCT04048382) on 7 August 2019 and approved by the San Diego State University (HS-2017–0187) institutional review board. This study began on 5 August 2019 and is estimated to continue through 31 March 2021. The clinical trial is in the pre-results stage.
- preventive medicine
- HIV & AIDS
- protocols & guidelines
- quality in health care
- public health
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Strengths and limitations of this study
There are no other known patient navigation trials targeting the pre-exposure prophylaxis (PrEP) cascade.
The trial will target each step of the PrEP cascade.
The trial will use peers as interventionists, which may increase scalability.
The sample size of the pilot trial is underpowered to fully test the efficacy of the intervention.
Reducing the number of new HIV infections is one of the goals of the National HIV/AIDS Strategy and an objective of Healthy People 2020.1 2 Men who have sex with men (MSM) are one of the most at-risk group for contracting HIV in the USA, comprising 67% of new diagnoses in 2016.3 It is estimated that 24.7% of sexually active MSM are at substantial risk for acquiring HIV.4 The HIV epidemic impacts some groups of MSM disproportionately, with Latino MSM comprising 25.1% of new HIV infections among MSM between 13 and 29 years of age.5 Recent modelling studies suggest that one out of four Latino MSM will be diagnosed with HIV within their lives, underscoring the vulnerability of Latino MSM to HIV infection.3
Pre-exposure prophylaxis (PrEP), a biomedical tool to reduce risk of HIV infection, has shown strong efficacy. When taken consistently, PrEP can reduce new incidence of HIV by up to 99%.6 Despite the promise of PrEP to transform HIV prevention, there remain significant barriers to PrEP use among those who would benefit most, including low awareness, low knowledge, medical mistrust, perceived high cost, lack of access, language barriers, low health literacy, cultural conceptions of masculinity and stigma.7–12 In a 2016 study conducted among 600 MSM between the ages of 18 and 29 years in Southern California, Latino MSM reported the lowest levels of PrEP use at 6.6%, compared with 9.8% and 13.9% for black and white participants, respectively.7 Although Latino MSM reported the lowest use of PrEP, they also reported the greatest willingness to use PrEP compared with white and black MSM. This discrepancy in willingness versus PrEP utilisation among Latino MSM emphasises the need to intervene to address barriers among this population.
There are a number of different steps that individuals must take to initiate, adhere to and persist in taking PrEP. Individuals must be aware of their HIV risk and eligibility for PrEP, be interested in taking PrEP, be linked to PrEP-related care, initiate PrEP-related care, be retained in PrEP-related care and maintain adherence to PrEP, with each step in this continuum of care associated with unique barriers.13 One approach that has been used to address multiple barriers to adhering to recommended healthcare is patient navigation (PN). Patient navigators work with the individual patient, the patient’s significant others, the healthcare system and community services to reduce delays and improve adherence in healthcare. PN has facilitated access to healthcare among other Latino populations,14–16 and peer PN may be an ideal intervention to aid in PrEP uptake among Latino MSM by assisting individuals in overcoming barriers to PrEP-related care. Thus, our research team has developed a peer PN intervention. To our knowledge, no known PN programmes for PrEP have been developed or pilot tested specifically for Latino MSM. This paper describes the design of a study to test a recently developed PN intervention to increase engagement in the PrEP continuum among Latino MSM.
Methods and Analysis
Using a randomised controlled trial design, a pilot test of the PN intervention will be conducted in collaboration with the Family Health Centers of San Diego (FHCSD), a federally qualified health centre.17 Bilingual research assistants will recruit 60 young adult Latino MSM at-risk for HIV in San Diego County, California; this sample size is well within the bounds of recommendations for pilot trials.18 After a research assistant obtains informed consent, participants will complete baseline surveys and the research assistant will individually randomise each participant to one of two conditions: usual care plus written information (UC) or PN. At 3-month and 6-month follow-up, participants will be asked to complete surveys. Individuals randomised to PN will also be asked to participate in a key informant interview at 6 months. Participants’ electronic health records (EHRs) will be reviewed at 6-month follow-up to assess their engagement in the PrEP continuum. The study methods and PN intervention will be reviewed for feasibility, acceptability, and the preliminary impact of the PN intervention in preparation for a future full-scale efficacy trial. In addition, the pilot test will evaluate preliminary impact on seven PrEP continuum-related primary outcomes (i.e., scheduled and attended PrEP consultation; PrEP prescription received; PrEP prescription filled; PrEP initiated; self-reported PrEP adherence; and PrEP follow-up medical appointment attended). Analyses will be performed under the intent-to-treat principle. Participants will be compensated with a $50 gift card to an online retailer at each of the three assessment time points (baseline, 3-month follow-up and 6-month follow-up) (see online supplemental appendices 1-3 for informed consents and WHO Trial Registration Data Set).
Patient and public involvement
As suggested by intervention mapping, a participatory planning group (PPG) of programme stakeholders guided the design of the PN intervention. The PPG includes a consultant and HIV expert, potential programme implementers, young Latino MSM and community members who interact with or deliver services to people who may benefit from the intervention. The PPG was instrumental in helping us develop the intervention materials and recruitment approaches. This group will continue to meet on an as-needed basis (with compensation for their time) and will assist with dissemination of research findings both in the community and in peer-reviewed publications and presentations.
The pilot RCT will take place in San Diego County, California. In 2017, San Diego had an estimated population of 3,337,685 people,19 33.9% of whom identified as Hispanic and 50.3% identified as male. Between 2012 and 2014, it was estimated that 3.9% of San Diego County’s population identified as a sexual minority.20 Our study is being conducted in partnership with FHCSD, which is San Diego’s largest federally qualified health centre, providing care to more than 140,834 patients in 2018. FHCSD delivers comprehensive healthcare in 42 sites throughout San Diego County. Each site provides a wide range of healthcare services to sexual and gender minority patients. Although we are partnering with FHCSD on this study, participants are recruited throughout San Diego County and obtain healthcare in various health systems, centres and practices in the community.
The following criteria are required for study inclusion: (1) age 18–29 years; (2) identifies as male; (3) identifies as gay/bisexual or reports having sex with men in past 12 months; (4) identifies as Latino/Hispanic; (5) self-reports being HIV uninfected; (6) resides in San Diego County, California; (7) speaks English or Spanish; (8) is willing and able to provide informed consent; and (9) reports at least one HIV risk factor as informed by Centers for Disease Control and Prevention (CDC) guidelines.21 MSM are at elevated risk for HIV if they report one of the following: (1) an HIV-positive sexual partner; (2) diagnosis of a bacterial sexually transmitted infection (STI) within the past 12 months; (3) engaging in condomless anal sex with a non-monogamous partner in the past 12 months; (4) engaging in commercial sex work in the past 12 months; (5) injection of illicit drugs and sharing of injection equipment in the past 12 months; or (6) engaging in drug treatment for injection drug use in the past 12 months. Individuals will be excluded if they self-report being HIV positive. The intervention is designed to meet the needs of MSM who self-report their gender identity as male, but other gender identities are allowed in the study. If a potential participant indicates that their gender identity is not ‘male’ (e.g., transgender, non-binary and gender fluid), then the participant will be informed that the study was designed for cis-male MSM and will then be invited to determine whether they feel that they will benefit from the study based on their gender identity. Participants who previously were prescribed or are currently taking PrEP will be included in the study. Participants are not required to seek care at FHCSD to be included in the study.
Non-probability (convenience) sampling will be used to recruit participants within the greater San Diego area via a variety of methods, including through FHCSD outreach and HIV/STI testing programmes, a Spanish language Latino MSM support group, gay-friendly events, such as Pride, and flyering local lesbian, gay, bisexual, and transgender (LGBT) community centres, gay-identified/friendly coffee shops, gyms and bars. We will also use online recruitment methods, including targeted ads through Facebook and Instagram and the use of geolocation social networking mobile applications tailored to sexual minority men (eg, Grindr, Scruff and Jack’d). Potential participants recruited using flyering or targeted ads will be requested to contact study personnel via email or telephone. A bilingual member of the study team will contact each potential participant via telephone to explain the study and screen for inclusion. The research assistants will be native Spanish speakers who are bilingual in English and Spanish; they will have some university education and research experience. If a potential participant screens positively for the study, an in-person baseline visit will be scheduled, in which the inclusion/exclusion criteria will be assessed in further detail. Reasons for non-participation of potential participants will be documented.
The research coordinator will use the Randomizer for Clinical Trial computer application to randomise each participant to either UC or PN via an iPad22 immediately following the baseline survey data collection. Randomizer for Clinical Trial will implement a blocked randomisation sequence (in blocks of four participants) to balance randomisation across the arms of the study. The randomisation sequence will be concealed from all members of the study team prior to randomisation.
Usual care intervention
Immediately following randomisation, the research team member will provide participants randomised to UC the CDC’s two-page PrEP Information Sheet in the participant’s preferred language (either English or Spanish). This two-page booklet includes the following information: (1) overview of PrEP; (2) eligibility for PrEP; (3) efficacy of PrEP; (4) safety of PrEP; and (5) obtaining, initiating and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at FHCSD. Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost.
Based on extensive formative research and using intervention mapping,23 the study team developed, pretested and produced the PN intervention materials. The produced PN intervention includes an introductory module, five educational modules (HIV prevention, PrEP introduction, PrEP efficacy, PrEP side effects and PrEP adherence) and a module focused on decision support. Patient education is facilitated using infographics, palm cards and a decision support tool. The educational modules are designed to be delivered as needed in addition to personalised strategies to improve access and decrease barriers to PrEP initiation and adherence. The intervention also consists of barrier reduction strategies to assist individuals with implementing HIV prevention, including the use of PrEP. Two part-time Spanish–English bilingual peer lay navigators hired by FHCSD will provide the PN intervention during the study. Navigators were hired based on their familiarity, as well as cultural and linguistic competence, with the intended audience, young Latino MSM. The study team will train the patient navigators using training manuals developed in formative research and via the Patient Navigation Research Program training approach.24
Following patient randomisation, the research coordinator will notify the patient navigators regarding the patient’s assignment to PN. A patient navigator will contact the participant to schedule the first in-person meeting at a time and location of the participant’s convenience. The navigators will provide services to patients using PN intervention manuals and materials the team has developed (see figure 1 for examples of PN services provided at each level of PrEP continuum). Services will generally focus on: (1) overcoming community, health system, interpersonal and individual barriers to accessing PrEP-related healthcare; (2) increasing each patient’s knowledge, attitudes and self-efficacy for initiating and adhering to PrEP; (3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and (4) sexual risk reduction counselling. PNs do not meet participants at their homes but at any safe location to conduct the intervention (e.g., private rooms in a library, clinic or community outreach centre). Meeting locations are coordinated between the participants and the PNs. PNs communicate with participants via text, phone call and videoconferencing based on the participant’s preference.
The FHCSD HIV services programme manager will provide day-to-day supervision of the patient navigators and will meet with each navigator weekly and document successes and challenges to PN intervention implementation through a weekly written report. The study staff also provide weekly supervision and will rate patient navigators’ delivery of the intervention, via audio recordings, using an intervention fidelity monitoring form.
Survey and interview data collection
Following informed consent, the research coordinator will administer self-report baseline surveys using Qualtrics in-person in the participant’s preferred language of Spanish or English, assess time required to complete surveys and note any participant difficulty in answering survey items. Participants will be asked to complete 3-month and 6-month follow-up surveys using a mixed mode approach, consisting of an initial Qualtrics (online) survey followed by an emailed survey if the Qualtrics survey is not completed. At baseline, 3-month follow-up and 6 month follow-up, participants will be asked to complete measures of PrEP knowledge, PrEP awareness, PrEP attitudes, PrEP barriers, PrEP efficacy beliefs, PrEP adherence, PrEP initiation, sexual behaviours, beliefs about medications, medication self-efficacy, mental health, substance use and social support (see table 1 for information regarding study surveys, including evidence of their validity and reliability). Self-report demographic information will be obtained at baseline. Self-report surveys assessing client satisfaction with PrEP-related healthcare services25 will be administered at 3-month and 6-month follow-up. Those randomised to PN will complete a self-report survey assessing satisfaction with the interpersonal relationship with the patient navigator26 at 3 months and 6 months. In addition, all participants randomised to PN will be contacted by telephone at 6 months to complete a key informant telephone interview to assess acceptability of the intervention; these key informant interviews will be conducted by members of the assessment team and not by PNs.
Measures were chosen following a literature review of existing validated instruments and psychometrically validated instruments were chosen when possible. However, as PrEP was only recently recommended for the prevention of HIV, there are few validated surveys measuring constructs related to PrEP. For these constructs, the team created new measures, adapting from existing scales when possible. Surveys not available in Spanish were translated using a dual panel approach.27–29
Medication Event Monitoring System (MEMS) device data collection
At baseline and 3-month follow-up, all participants will be asked if they have obtained a prescription for PrEP. Those who indicate that they have been prescribed PrEP and have taken at least one pill will be asked to track their PrEP adherence via a MEMS device.30 A MEMS device is a standard prescription bottle that includes a larger lid containing a MEMS monitoring cap. During the baseline or at a 3-month follow-up visit, the research coordinator will give participants a MEMS device with instructions for its use. Participants will be instructed to place all PrEP pills into a MEMS container so when a pill is removed, the device will record date and time of removal of the medication dose using a small microcircuit. A medication ‘event’ is removal of bottle closure, followed by replacement of closure. A study staff member will collect MEMS devices from participants in-person at the 3-month and/or 6-month follow-up and connect them to a MEMS Reader, which transfers data to a secured server via a secured web platform. Timing adherence will be calculated as percentage of time each participant took PrEP as prescribed by determining number of doses of PrEP taken at 24-hour intervals for a once daily PrEP regimen and dividing it by number of days adherence was monitored with MEMS.
Medical record data collection
We will collect the following data from EHRs 6 months following study enrollment after obtaining a written release of information: (1) date(s) initial appointment to speak to a healthcare provider regarding PrEP was scheduled; (2) date participant attended an initial appointment to discuss PrEP; (3) dates and number of prescriptions written for PrEP by a healthcare provider; (4) date the first follow-up visit related to PrEP was scheduled; and (5) dates the participant attended follow-up appointments related to PrEP. We will document EHR data regarding PrEP initiation and adherence, barriers to PrEP adherence, exams and laboratory tests required to obtain an initial or follow-up PrEP prescription, side effects attributed to PrEP, diagnosis and treatment of illness during the study, prescription medications, comorbid health conditions and history of STI testing. We will also note whether the EHR indicates that participants decided to cease taking PrEP and the date of discontinuation.
PN intervention encounter data
Using an approach developed by the Patient Navigation Research Program,31 patient navigators will record process data related to the PN services provided, including: (1) number of encounters; (2) length of time of each encounter; (3) barriers experienced by patients; and (4) actions taken to reduce barriers. The patient navigators will also be asked to keep detailed qualitative notes regarding telephone, text and in-person encounters with participants, including participants’ progress in the PrEP continuum, successes in implementing the PN intervention and challenges in implementing the PN intervention.
A feasibility evaluation will examine areas critical to success of a larger research study. First, we will evaluate recruitment strategies by assessing the number of individuals eligible for the study, number with whom we could establish contact, number who agreed to participate or did not, reasons for non-participation, and ineligibility and difficulty with implementing the randomisation process. Second, we will assess methods of data collection including participant time burden for completing baseline surveys, participant difficulty in answering survey questions, difficulty of using MEMS, reliability of surveys, number and types of missing survey data, timing of follow-up data collection and rates of completion of follow-up surveys. Third, we will examine feasibility and processes of delivering the PN intervention by assessing the actions taken by the patient navigators and frequency and type of encounters. Data will be examined descriptively to identify areas for improvement of the study or PN intervention methods before a larger research study is initiated.
An extensive acceptability evaluation will examine how both individuals randomised to the PN intervention and those involved in implementing the programme reacted to the intervention.32 Data will be collected for the acceptability evaluation using multiple quantitative and qualitative methods, including patient navigator encounter logs, patient navigator client notes, patient navigator supervisor notes, participant surveys, and participant key informant interviews. Quantitative acceptability data will be collected from pilot test participants at the 6-month follow-up using validated surveys assessing satisfaction with PrEP-related healthcare25 and Interpersonal Relationship with the Navigator,26 as well as from the patient navigators through the PN intervention encounter logs. Qualitative data will be collected from pilot test participants at the 6-month follow-up via three open-ended survey questions assessing the aspect of the PN intervention participants liked the best, the aspect of the PN intervention participants liked the least and one thing that could be changed about the PN intervention25 as well as via a brief telephone key informant interview conducted by a trained bilingual research coordinator. The semistructured key informant interviews will be conducted in the participant’s preferred language and will use a 28-item standardised interview guide designed using Sekhon et al’s33 theoretical framework of acceptability. Interviews will last approximately 45 min and will be recorded, transcribed verbatim and translated (if necessary) into English. In addition, both the patient navigators and the supervisor of the patient navigators will record observations regarding the implementation of the PN intervention, including success and challenges.
Consistent with NIMH requirements, a data monitoring committee is not required given this is not a phase III clinical trial and because of the low-risk nature of this exploratory study.
Qualitative data (key informant interviews, navigator qualitative notes and supervisor notes) will be saved in a text file to import into NVivo34 for analysis. The study principal investigators (PIs) will review the qualitative data using a content analysis technique, which identifies emergent themes occurring during discussion. Code mapping35 will be used to develop a preliminary set of codes (themes) corresponding to each potential strength of the PN intervention as well as every potential aspect for improvement. Then, the co-PIs will independently code the remaining data and meet to discuss and achieve consensus in coding. Once coded, the data will be summarised by theme. These data will be used to modify the PN intervention, if necessary, or will provide further indication that the PN intervention should be tested in a larger scale study.
All quantitative data will be summarised descriptively to determine aspects of the PN intervention that worked well and potential areas of improvement of the PN intervention. Our biostatistician will be blinded to intervention assignment for participants and will conduct statistical analyses using SAS V.9.4.36 Univariate statistics will be conducted for outcomes measured at baseline and 6-month follow-up to describe sample characteristics between the two groups (UC vs PN). Attrition in the two groups will be compared. Characteristics of individuals with missing values and individuals with no missing values will be studied. Multiple imputation technique will be implemented and sensitivity analysis will be conducted to assess if missing data is at random. Assumptions of statistical tests will be evaluated. For assessing preliminary impact, the primary outcomes are seven behaviours associated with the PrEP care continuum (i.e., appointment scheduled for PrEP consultation; appointment attended for PrEP consultation; PrEP prescription received; PrEP prescription filled; PrEP initiated; self-reported PrEP adherence over the past 7 days; and PrEP follow-up medical appointment attended).
To test the preliminary impact of the intervention, a series of logistic regression models will be conducted, with each of the six binary PrEP continuum primary outcome variables set as a criterion: (1) appointment scheduled for PrEP consultation; (2) appointment attended for PrEP consultation; (3) PrEP prescription received; (4) PrEP prescription filled; (5) PrEP initiated; and (6) PrEP follow-up medical appointment attended. In addition, we hypothesise that receipt of the PN intervention will be associated with increased self-reported PrEP adherence over the past 7 days (also a primary outcome variable). To test the preliminary impact on the two measures of self-reported PrEP adherence, we will conduct two linear regression analyses with intervention group assignment entered as the independent variable and each measure of PrEP adherence entered as the dependent variable. Potential demographic variables (e.g., age) will be assessed for inclusion in the models as well. Finally, linear mixed models will be conducted to examine changes in: (1) barriers to PrEP-related care; (2) PrEP knowledge, (3) PrEP efficacy beliefs; (4) medication beliefs; (5) PrEP attitudes; and (6) medication self-efficacy. Linear mixed models allow us to account for the dependence of the repeated measures. Different covariance structures will be implemented, and the information criterion such as AIC or BIC will be used for model selection. We hypothesise that participants randomised to PN will have greater engagement in PrEP continuum behaviours compared with participants randomised to UC. Since data analyses are exploratory, and there is not adequate statistical power to evaluate efficacy of the PN intervention, these tests can only provide information regarding data trends and effect sizes. If the study and PN intervention methods are found to be feasible and acceptable, a larger study with adequate statistical power will be conducted to appropriately evaluate the efficacy of the PN intervention.
Young adult Latino MSM are disproportionately at risk for HIV infection.5 PrEP has the potential to yield substantial benefits in reducing HIV incidence among vulnerable populations, yet Latino MSM are one of the least likely at-risk groups to use PrEP.7 37 The study described in this paper has the potential to begin to address this ethnic health disparity by pilot testing a peer PN intervention specifically adapted for young adult Latino MSM. Study findings will indicate if, and what types of, revisions should be made to the PN intervention. Potential study limitations include the lack of generalisability to other populations at risk for HIV, the lack of data collection from other community stakeholders, the need for potential participants to be proactive to participate in the study, the lack of concealment of randomisation block size and the potential for loss to follow-up. Results from this pilot trial will inform the design of a subsequent large-scale RCT that will be designed to fully test the efficacy of the PN intervention in impacting key gaps in the PrEP continuum, including adherence to PrEP after initiation and long-term retention in PrEP-related care. If subsequently found to be efficacious, this culturally tailored PN PrEP intervention has the potential to be scaled-up throughout federally qualified health centres across the country, which may decrease ethnic disparities seen in HIV.
Ethics and dissemination
This study was approved by the San Diego State University institutional review board (Protocol number: HS-2017–0187) and is registered at ClinicalTrials.gov (NCT04048382; https://clinicaltrials.gov/ct2/show/NCT04048382). All staff are trained on research ethics. Peer navigators are trained on peer navigation and receive confidential weekly supervision by both principal investigators who have experience in clinical supervision and peer navigation training. Confidentiality is ensured at all times during this research process. Identifiable data are only shared with authorised study staff and kept in locked files and password-protected computers; identifiable information will not be shared during dissemination activities. All participants are provided a unique identifier to further protect participants’ identity, and all qualitative data are deidentified. Informed consent is obtained from all eligible participants by trained study staff. Participants are able to stop participation in the study at any time. Participants are provided resources to access PrEP and sexual healthcare regardless of the condition to which they are assigned (PN or usual care). All protocol modifications will be approved by the San Diego State University institutional review board and described in dissemination efforts on study completion.
The intervention development process and plan, as well as the results of the study, will be shared through peer-reviewed journal publication, conference presentations, and healthcare system and community presentations.
The authors would like to thank Guillermo Martin, Sergio Velasquez and Sheldon Morris for their support and assistance.
Contributors The authors confirm that they have met the following authorship criteria: (1) substantial contributions to the conception or design of the work (AJB, CBR, C-DL and KJW), or the acquisition, analysis or interpretation of data (AJB, JRG, CBR, C-DL, CMC, KAN, KML, NCL, IJJ, DR, RACA, JPB, MF and KJW); (2) drafted the work or revised it critically for important intellectual content (all authors); (3) gave final approval of the version published (all authors); and (4) agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (all authors).
Funding Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R34MH114699. NL’s efforts on this research were supported by the National Cancer Institute of the National Institutes of Health under award numbers U54CA12384 and U54CA132379. IJJ's and DR’s efforts on this research were supported by the National Cancer Institute of the National Institutes of Health under award number R25CA132699 and under the National Institutes of Health Initiative for Maximising Student Development, under award number 5R25GMO58906.
Disclaimer The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.